Prevention of myocardial injury with rosuvastatin during coronary intervention study
- Conditions
- Coronary Artery Disease
- Registration Number
- JPRN-UMIN000003265
- Lead Sponsor
- ippon Medical School
- Brief Summary
The incidence of periprocedural MI did not significantly differ between the high and low-dose groups (8.7% vs 18.7%, p = 0.052). In patients who were not taking statins at the time of enrollment, high-dose rosuvastatin significantly suppressed periprocedural MI compared with the low dose. The difference was not significant in patients who were already taking statins .
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 232
Not provided
1. Patients with severe renal disease (sCR=>3.0, urine protein +++ urine OB +++) or liver disease (AST>100IU/l, ALT>100IU/l, T-bil>3.0mg/dl, PT<60%, albumin<2.8g/dl) 2. ACS patients who need to receive emergency revascularization 3. Patients with no-PCI indication lesion such as LMT 4. in-stent or para-stent restenosis 5. Patients who cannot take statin 6. malignancy
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method